Company news
Alterity Therapeutics Ltd. news in 2016
Alterity Therapeutics Ltd.'s news releases, calls and decks from 2016, newest first.
Business Update
December 23, 2016
S&P DJ Indices Announces March Quarterly Review
November 7, 2016
S&P DJ Indices Announces March Quarterly Rebalance
November 6, 2016
Prana provides regulatory update for PBT2
November 2, 2016
Prana announces $4.8 million R&D refund
October 30, 2016
New Reach2HD data presented at American Neurological Assoc.
October 18, 2016
Prana announces $6.5 million R&D refund
May 9, 2016
FDA Orphan Drug Designation for PBT2 for Huntington Disease
March 30, 2016
Prana to commence Phase 11b trial on PBT2
March 30, 2016
Prana selects lead PD drug candidate for development
March 30, 2016
Prana Provides Analysis of PBT2 Therapeutic Strategy for AD
March 30, 2016
Investment by Quintiles, Placement of 225 million Shares
March 30, 2016
Appendix 4E for the Year Ended 30 June 2010
March 30, 2016
Quintiles Makes Second Investment in Prana
March 30, 2016
Prana`s PBT2 Phase II trial receives funding from ADDF
March 30, 2016
Prana Raises A$6.19 million in a Private Placement
March 30, 2016
Prana accelerates PBT2 commercial development
March 30, 2016
PBT2 - Directly Restores Neurons Critical to Cognition
March 30, 2016
Prana`s PBT2 Directly Restores Neurons Critical to Cognition
March 30, 2016
Prana Receives Michael J. Fox Foundation Grant
March 30, 2016
Prana Announces At-the-Market Issuance Program
March 30, 2016
PBT2 reverses the loss of synaptic activity in neurons
March 30, 2016
Landmark Publication Endorses Prana`s Strategy
March 30, 2016
Key Patent for Parkinson`s Drug PBT434 Secured in USA
March 30, 2016
Australian Government funds study into benefits of PBT2
March 30, 2016
Significant Promise in the Fight Against Alzheimers Disease
March 30, 2016
Prana Receives Recommendation to Proceed with Clinical Trial
March 30, 2016
Prana Provides Clinical Trials Update
March 30, 2016
Prana Doses First Patient in the IMAGINE Phase II Trial
March 30, 2016
Prana Comments on Neurology Publication Huntington Data
March 30, 2016
First Patient Enrolled in Phase II Huntington Disease Trial
March 30, 2016
Appendix 4E - Preliminary Financial Report
March 30, 2016
Appendix 4C - Quarterly report
March 30, 2016
Pranas PBT434 shows potential as treatment in PD
March 30, 2016
Pranas PBT434 Inhibits PD Protein & Brain Cell Death
March 30, 2016
Pranas PBT2 Reduces Tau Related Cognitive Impairment
March 30, 2016
Prana Provides Huntington Disease Trial Update
March 30, 2016
Prana Provides Clinical Trials Safety and Progress Update
March 30, 2016
Prana Doses 1st Patient in PBT2 Alzheimers Extension Study
March 30, 2016
Prana details PBT2 data on reduced Tau Cognitive Impairment
March 30, 2016
Prana Completes Recruitment in Huntington Trial
March 30, 2016
Prana Completes Recruitment in Alzheimers Trial
March 30, 2016
Prana Completes Phase 2 Huntington Disease Trial with PBT2
March 30, 2016
Prana Announces Successful A$7 milion Capital Raising
March 30, 2016
Prana announces $5.8 million R&D refund
March 30, 2016
New York Academy of Sciences Symposium Discusses PBT2
March 30, 2016
New benchmark test to assess HD patients in clincial trials
March 30, 2016
Prana Updates Progress on PBT2 Trials
March 30, 2016
Pranas PBT2 Reverses Memory Loss in Normal Aging
March 30, 2016
Prana Provides Update on Clinical Trials for Alzheimers
March 30, 2016
Decks in 2016
- Prana Biotechnology — Investor Presentation (April 2016)
Investor deck · 18 slides · Apr 22, 2016
- Prana Biotechnology — World Orphan Drug Congress (April 2016)
Conference · 18 slides · April 2016